## Abstract In a Chinese myoclonus‐dystonia syndrome (MDS) family presented with a phenotype including a typical MDS, cervical dystonia, and writer's cramp, genetic analyses revealed a novel 662 + 1insG heterozygous mutation in exon 5 in the ε‐sarcoglycan (__SGCE__) gene, leading to a frameshift wi
Lack of mutations in the epsilon-sarcoglycan gene in patients with different subtypes of primary dystonias
✍ Scribed by Kathrin Grundmann; Ulrike Laubis-Herrmann; Dirk Dressler; Juliane Vollmer-Haase; Peter Bauer; Manfred Stuhrmann; Thorsten Schulte; Ludger Schöls; Helge Topka; Olaf Riess
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 62 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Primary dystonias represent a clinically and genetically heterogeneous group of movement disorders. Mutations in the ϵ‐sarcoglycan (SGCE) gene have been found recently to cause myoclonus–dystonia (MD). Considerable clinical variation of SGCE mutation carriers leads to the hypothesis that mutations in the SGCE gene might also be relevant for other subtypes of dystonias. To determine the contribution of mutations in the SGCE gene in patients with different subtypes of dystonias, we analyzed the coding sequence of the SGCE gene in a group of 296 patients with a clinical phenotype of primary dystonia and in 2 patients with a clinical phenotype of myoclonus–dystonia. Patients with mutations in the DYT1 gene were excluded. We could not detect a mutation in the SGCE gene in any of the 298 patients. Our results suggest that mutations in the SGCE gene cannot be held responsible for other subtypes of primary dystonia. © 2004 Movement Disorder Society
📜 SIMILAR VOLUMES
Myoclonus-dystonia (M-D) is an autosomal dominant disorder characterized by myoclonic and dystonic muscle contractions that are often responsive to alcohol. Myoclonic movements of the arms and axial muscles are associated with dystonic movements of the neck and arms in more than 50% of the patients.